BIRC5 and pancreatic neoplasm: To date, the survivin‐2B80–88 peptide vaccine has exhibited a certain degree of therapeutic efficacy in HLA‐A24‐positive patients with oral, colorectal, breast, and pancreatic cancer [25, 26, 27, 28].